Cancer mortality following treatment for adult hyperthyroidism

被引:251
作者
Ron, E [1 ]
Doddy, MM
Becker, DV
Brill, AB
Curtis, RE
Goldman, MB
Harris, BSH
Hoffman, DA
McConahey, WM
Maxon, HR
Preston-Martin, S
Warshauer, ME
Wong, FL
Boice, JD
机构
[1] NCI, Radiat Epidemiol Branch, NIH, Bethesda, MD 20892 USA
[2] Cornell Univ, Med Ctr, New York Hosp, New York, NY 10021 USA
[3] Vanderbilt Univ, Nashville, TN USA
[4] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA
[5] Res Triangle Inst, Res Triangle Pk, NC 27709 USA
[6] George Washington Univ, Washington, DC 20052 USA
[7] Mayo Clin, Rochester, MN USA
[8] Univ Cincinnati, Med Ctr, Cincinnati, OH 45267 USA
[9] Univ So Calif, Los Angeles, CA 90089 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 1998年 / 280卷 / 04期
关键词
D O I
10.1001/jama.280.4.347
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context.-High-dose iodine 131 is the treatment of choice in the United States for most adults with hyperthyroid disease. Although there is little evidence to link therapeutic I-131 to the development of cancer, its extensive medical use indicates the need for additional evaluation. Objective.-To evaluate cancer mortality among hyperthyroid patients, particularly after I-131 treatment. Design.-A retrospective cohort study. Setting.-Twenty-five clinics in the United States and 1 clinic in England. Patients.-A total of 35 593 hyperthyroid patients treated between 1946 and 1964 in the original Cooperative Thyrotoxicosis Therapy Follow-up Study; 91% had Graves disease, 79% were female, and 65% were treated with I-131. Main Outcome Measure.-Standardized cancer mortality ratios (SMRs) after 3 treatment modalities for hyperthyroidism. Results.-Of the study cohort, 50.5% had died by the end of follow-up in December 1990. The total number of cancer deaths was close to that expected based on mortality rates in the general population (2950 vs 2857.6), but there was a small excess of mortality from cancers of the lung, breast, kidney, and thyroid, and a deficit of deaths from cancers of the uterus and the prostate gland. Patients with toxic nodular goiter had an SMR of 1.16 (95% confidence interval [CI], 1.03-1.30). More than 1 year after treatment, an increased risk of cancer mortality was seen among patients treated exclusively with antithyroid drugs (SMR, 1.31; 95% CI, 1.06-1.60). Radioactive iodine was not linked to total cancer deaths (SMR, 1.02; 95% CI, 0.98-1.07) or to any specific cancer with the exception of thyroid cancer (SMR, 3.94; 95% CI, 2.52-5.86). Conclusions.-Neither hyperthyroidism nor I-131 treatment resulted in a significantly increased risk of total cancer mortality. While there was an elevated risk of thyroid cancer mortality following I-131 treatment, in absolute terms the excess number of deaths was small, and the underlying thyroid disease appeared to play a role. Overall, I-131 appears to be a safe therapy for hyperthyroidism.
引用
收藏
页码:347 / 355
页数:9
相关论文
共 40 条
[31]   THYROID-CANCER AFTER EXPOSURE TO EXTERNAL RADIATION - A POOLED ANALYSIS OF 7 STUDIES [J].
RON, E ;
LUBIN, JH ;
SHORE, RE ;
MABUCHI, K ;
MODAN, B ;
POTTERN, LM ;
SCHNEIDER, AB ;
TUCKER, MA ;
BOICE, JD .
RADIATION RESEARCH, 1995, 141 (03) :259-277
[32]   INCIDENCE OF LEUKEMIA FOLLOWING TREATMENT OF HYPERTHYROIDISM - PRELIMINARY REPORT OF COOPERATIVE THYROTOXICOSIS THERAPY FOLLOW-UP STUDY [J].
SAENGER, EL ;
THOMA, GE ;
TOMPKINS, EA .
JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1968, 205 (12) :855-&
[33]   ISSUES AND EPIDEMIOLOGIC EVIDENCE REGARDING RADIATION-INDUCED THYROID-CANCER [J].
SHORE, RE .
RADIATION RESEARCH, 1992, 131 (01) :98-111
[34]  
Tompkins E, 1970, MED RADIONUCLIDES RA, P431
[35]   SPECTRUM OF THYROID DISEASE IN A COMMUNITY - WHICKHAM SURVEY [J].
TUNBRIDGE, WMG ;
EVERED, DC ;
HALL, R ;
APPLETON, D ;
BREWIS, M ;
CLARK, F ;
EVANS, JG ;
YOUNG, E ;
BIRD, T ;
SMITH, PA .
CLINICAL ENDOCRINOLOGY, 1977, 7 (06) :481-493
[36]  
*US DHEW, 1967, PHS PUBL, V1693
[37]  
Volpe R, 1989, THYROID FUNCTION DIS, P214
[38]  
WILLIAMS ED, 1986, LANCET, V2, P456
[39]  
World Health Organization,, 1957, MAN INT STAT CLASS D
[40]  
ZANZONICO P B, 1989, Journal of Nuclear Medicine, V30, P833